STAT April 15, 2021
Katie Palmer

For the 1.6 million people in America living with type 1 diabetes, a continuous glucose monitor can be a lifesaver.

Since the first CGM was approved by the Food and Drug Administration in 1999, the diabetes community has advocated for lower prices and better insurance coverage for the quarter-sized devices, which regularly sample a proxy for blood glucose levels and can sound an alarm when they swing too high or too low. The cost-cutting has had an unexpected side effect: Today, glucose monitors are so cheap they’ve spawned a new crop of digital health startups selling the devices to consumers, many of whom don’t have diabetes.

Glucose monitors are only approved in the U.S. for use in people with diabetes...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Digital Health, Patient / Consumer, Provider, Technology, Wearables
'Healthcare platform Doctolib has conquered France — but can it take on Europe?'
Digital Health Intelligence Market Analysis: Medical Device Cyber Security
Teladoc Plots Course Correction in Wake of BetterHelp’s Disappointing First Quarter
Royal Papworth CIO presents six actions for trusts’ AI journey
The ins and outs of telehealth coding

Share This Article